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Manuscript: BMJ Open. Bmjopen-2016-014928 Title: Diagnosis and treatment for hyperuricemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements.
GENERAL Comments:
This paper describes a thorough protocol to coduct a systematic review of the clinical guidelines and consensus statements concerning the diagnosis and treatment of hyperuricemia and gout. The authors state that their ultimate objective is to provide recommendations based on their thorough review of the published recommendations.
To achive this objetive the authors will use The Appraisal of Guidelines for Research and Evaluation (AGREE) II, which is an instrument validated and rigorously developed to weight the evidences and step by step to assess the miriad of documents that have dealt with these issues.
Overall the text is very well written, the task is enormous and their attitude and capacity should be stimulated because this is a much needed work. This statement is based not only on what the authors point out concerning the discrepancies among guidelines and documents on hyperuricemia and gout (for instance, is it appropriate to prescribe urate lowering therapy during acute gout flares, qhich of the xanthine oxidase inhibitors should be given first, or tarjet serum urate level in non-tophaceous and tophacepous gout), but also 
GENERAL COMMENTS
This is a well written protocol for an interesting systematic review of guidelines and consensus statements for gout and hyperuricaemia.
However, I do have a few comments and concerns that the authors should consider: 1. In the abstract the sentence in the discussion is weak, could the authors make a more positive statement.
2. In the methods, please could the authors add their justification for searching from 2000 onwards.
3. Inclusion criteria state that the guidance needs to be published in English or Chinese, which does restrict the usefulness of the systematic review. Would it be possible to include published guidelines in other languages and have these translated if necessary or look for English versions.
4. Related to the previous point, there may be guidelines published in English from countries whose first language is not English. It may restrict the searches too much to only search in specific regions.
5. Resources such as the TRIP Database and Epistemonikos are also helpful for looking for clinical guidelines.
6. The search strategy has inaccuracies, such as missing spaces between terms and line 5 "hyperuric?emia/" should be "hyperuric?emia.ti"(or .m_titl. if selecting a title search)
7. Was a librarian or information specialist consulted to help with developing the search strategy? There are search filters available from The InterTASC Information Specialists' Sub-Group (ISSG) -https://sites.google.com/a/york.ac.uk/issg-search-filters-resourcefor finding guidelines and recommendations that might suggest other relevant search terms. Other terms for gout and hyperuricaemia may also be found by looking at other published systematic reviews on the topic, particularly Cochrane reviews 8. Another important point is that it would be more helpful for readers of the review to have more than scores from the quality appraisal. Perhaps a more narrative appraisal and discussion based on the domains that are poor or well reported/conducted for each guideline, which will give more depth to the review findings. Also to consider the inconsistency in the guideline recommendations in relation to the different domains in the AGREE appraisal. . These urate deposits in most cases elicit inflammation that will ultimately cause articular damage. Thus, the paradigm that "asymptomatic hyperuricemia should not be treated" has been challanged in recent years and this proyect may help to clarify several points concerning this important issue. Among the questions that this study may contribute to answer in the long term and concerning asymptomatic hyperuricemia are the followings: -What is the urate level and for how long needs to be present in order an articular image technique, such as a sonographic study, be cost-effective to assess urate deposits? -Where are urate deposits more frequently found in patients with asymptomatic hyperuricemia? -What would be the best treatment (urate lowering therapy) to clear-off these urate deposits and for how long? What is the optimal urate level tarjet? How should we monitor urate deposits clearance?
VERSION 1 -AUTHOR RESPONSE
Concerning gout, the authors have alrady delineated the most important questions that guidelines should answer and their study will undoubtedly contribute to point out the discrepancies already detected among guidelines. We do not have such a thourough study and thus, my most entusiasthic recommendation for this study to be carried out. The protocol is excellent, all issues have been considered with the AGREE II instrument and I sincerely look forward to read the paper.
RE: We deeply appreciated your patient summary of the manuscript and kind exploration of the scope and significance of our promoted work. Inspired by your comments, we further clarified some of the questions that our promoted study might contribute to answer (Page 9). This data exemplifies the accuracy and appropriateness of the reviewed paper.
RE: Thank you for providing additional evidence for our data. The work conducted by Torres RJ and colleagues [1] was a genetic study involving 104 gout patients, the result of which showed that 74% of all participants were diagnosed with arterial hypertension. The study cited in our draft protocol [2] was a survey of more than 500 patients with gout, the result of which found hypertension present in more than three-quarters of included patients. With careful review of both papers, we revised our expression to "hypertension was presented in at least 74% gout patients" (page 4) and added the study of Torres RJ and colleagues [1] as a reference. Thanks.
REVIEWER: 2 1. The literature reviewed is absolutely incomplete. English Language is a major issue.
RE: Thank you for comment on our limitation of language restriction. We admitted the importance of including guidelines published from regions not using English as first language. But since we were not able to read non-English and non-Chinese documents, and since non-English guidelines received limited international influence, we had to restrict our search strategies to the English versions of guidelines published from these regions to minimize the limitation of language.
Why is the Cochrane Database left out?
RE: Thank you for suggestions. Since there is not any Cochrane database specifically for guidelines, Cochrane Database was not included in our search sources for guidance documents. Nevertheless, we agreed with the reviewer that Cochrane Database was very important in evidence-based medicine. We had carefully searched the CDSR database for systematic reviews for HUG guidelines as preparation for this work, but did not identify any systematic review of guidelines on the current research topic.
3. Neither of the EULAR guidelines from 2014 or 2016 have been discussed. There are several reviews of current practice guidelines available not only in the rheumatology literature but also in the nephrology literature. BSR has another set of guidelines which have not been discussed at all. There are several reviews of current practice guidelines available not only in the rheumatology literature but also in the nephrology literature. IOM, WHO and Guidelines International Network have clear criteria which were not discussed at all.
RE: Thank you for your suggestions. We admitted that these guidance documents and criteria were critically important in this topic. However, since our submitted paper was not a final review but a protocol, we did not include all the guideline documents in the current manuscript. The eligible guidelines and established criteria including those mentioned in the comments will be discussed in the final review. Nevertheless, in order to provide more sufficient background, we added the contents involving the EULAR guideline from 2016 and the BSR guideline from 2007 to the introduction section (Page 5).
4. The authors propose using the AGREE 2, I do not understand why when at the same time they quote AHRQ evidence reports which used GRADE methodology to appraise data.
RE: We felt sorry for this misunderstanding but we did not quote AHRQ evidence reports to appraise any data. We planned to use merely the AGREE II instrument to appraise the included guidelines. If you were referring to the PRISMA-P checklist we provided, we would like to clarify that we were only using it as a guidance to develop our protocol. And the use of it was encouraged by the defined scope of PRISMA-P [3] and was required by the journal BMJ Open [4] .
5. 6 mg/dL is NOT the saturation point of urate -it is 6.8 mg/dL. RE: Thank you for reminding us of this inaccurate expression. We revised the original sentence to "The target serum urate level is generally set as below 6mg/dL, which is lower than the saturation point for monosodium urate (6.8mg/dL)". (Page 5)
6. I am sorry but this is not the first systematic review of clinical practice guidelines in gout.
RE: Thanks for your comment. However, we did not identify any systematic review of CPGs and consensus in gout providing an overview of its diagnosis and treatment in commonly searched English and Chinese databases (including PubMed, EMBase, CDSR, CBM, Wanfang, CNKI, etc.) after careful literature review. Nonetheless, due to the language limitation, the non-English and nonChinese literatures were not investigated in our study. Some unpublished study might also be left out if their abstracts were not indexed in common databases.
We did find several well-written and valuable narrative reviews [5] [6] [7] in our pilot literature search, which indeed helped our study and others'. However, none of them were considered to be systematic reviews without presenting the standardized methodology of systematic collection of the literatures and quality assessment. In the promoted study, we will adopt a comprehensive search strategy and will conduct thorough literature search in PubMed, EMBase, Chinese databases (CBM and Wangfang), guideline databases, Google, and Google Scholar, in order to identify as sufficient guidance documents as possible.
We added the aforementioned reviews [5] [6] [7] into the revised manuscript (page 4, 5, 10) to better illustrate the background of our work.
REVIEWER: 3 1. In the abstract the sentence in the discussion is weak, could the authors make a more positive statement.
RE: The discussion section in the abstract was removed according to the editor's comments.
RE: Thank you for your comment. We have seriously considered this issue at the time of developing this protocol. The original strategy of searching from 2000 onwards was intended to include only the latest guidelines. However, we admitted that this might make results less adequate. And hence we would like to remove this limitation of the year of publication in the current manuscript.
RE: Thank you for raising concerns on the limitation of language. Similar with our response to a previous comment, per our search strategies, if a guideline on hyperuricemia and gout had been published in English, regardless of the first language of the organization which produced it and of the language used for the original version, the guideline will be searched and included.
